DiaSorin Strikes Dx Partnership With MeMed To Address Antibiotic Overuse
Executive Summary
First licensing agreement for MeMed adds its immune system-based protein signature test to DiaSorin’s LIAISON test menu.
You may also be interested in...
MeMed Ready To Partner On IVD Technology That Can Cut Antibiotic Overuse
MeMed has received CE Marking for its diagnostic test MeMed BV and point-of-need platform MeMed Key, which uses the human immune system to distinguish between bacterial and viral infections to prevent antibiotic overuse.
Start-Up Spotlight: MeMed, Making Infectious Disease Dx Clearer With Immune Responsive Signatures
Israeli company MeMed has developed a proprietary diagnostic platform which uses proprietary immune system biomarkers to rapidly distinguish between viral and bacterial infections. The firm already has a CE -marked lab-based product, ImmunoXpert, which has been validated in three studies, the last of that trilogy having just published results confirming the test's ability to accurately distinguish between bacterial and viral infections.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.